| Project/Area Number |
25462470
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Urology
|
|---|
| Research Institution | The University of Tokyo |
|---|
Principal Investigator |
ENOMOTO Yutaka 東京大学, 医学部附属病院, 臨床登録医 (20280927)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
KAKIMI Kazuhiro 東京大学, 医学部附属病院, 教授 (80273358)
MATSUSHITA Hirokazu 東京大学, 医学部附属病院, 助教 (80597782)
NAKAGAWA Tohru 東京大学, 医学部附属病院, 講師 (40591730)
川合 剛人 東京大学, 医学部附属病院, 助手 (60343133)
|
|---|
| Project Period (FY) |
2013-04-01 – 2016-03-31
|
| Project Status |
Completed (Fiscal Year 2015)
|
| Budget Amount *help |
¥2,990,000 (Direct Cost: ¥2,300,000、Indirect Cost: ¥690,000)
Fiscal Year 2015: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000)
Fiscal Year 2014: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2013: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
|
|---|
| Keywords | 腎細胞癌 / 樹状細胞療法 / インターフェロン / 分子標的薬 |
|---|
| Outline of Final Research Achievements |
We conducted a phase I/II clinical trial for patients with metastatic renal cell carcinoma (mRCC). Dendritic cell (DC) vaccine was generated using autologous tumor lysate as the antigen source. DC vaccine was administered after nephrectomy together with either IFNα or sunitinib. Five patients with mRCC were enrolled within the study period. Patients received 10.6 vaccinations on average, and no severe adverse event was observed. Immunological responses after vaccination and concomitant administration of sunitinib were analyzed for eight patients including those who were enrolled before the current grant was implemented. We demonstrated that immunosuppressive cells decreased after vaccination and sunitinib administration, which suggested that sunitinib may enforce immunological anti-tumor effect.
|
